Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as growth slows, but investors

Investing.com -- Novo Nordisk shares have slipped over 2% premarket on Thursday after the company made an unsolicited bid to acquire Metsera, a U.S. obesity drug developer, in a move BMO Capital described as “an over-the-top bid” that complicates Pfizer ’s ongoing takeover attempt.

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his position amid an ongoing probe into his “personal conduct”; FDA reverses course on approval requirements for uniQure’s Huntington’s gene therapy;